• 1)Voluntarily sign written informed consent;

• 2)Age ≥18, ≤75 years old, male and female;

• 3 )Estimated survival ≥ 3 months;

• 4\) ECOG physical fitness score was 0-2;

• 5\) EBV positive nasopharyngeal carcinoma was diagnosed;

• 6\) Positive target detection;

• 7\) At least one measurable lesion according to RECIST V1.1 solid tumor evaluation criteria;

• 8\) Patients with recurrent/metastatic nasopharyngeal carcinoma who had previously failed second-line or higher systemic therapy;

• 9\) Monopheresis or venous blood collection venous access can be established, and there are no other contraindications for blood cell separation;

• 10\) Full organ and bone marrow function,

• 11\) Toxicity and side effects left by previous anti-tumor therapy (radiotherapy, chemotherapy, targeted therapy, etc.) ≤ grade 1 (CTCAE 5.0);

• 12\) Fertile subjects (male or female) must use effective medical contraception during the study period and for 6 months after the end of administration. In female subjects of reproductive age, a negative pregnancy test should be performed within 72 h prior to the first dose.